JP2018530549A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018530549A5 JP2018530549A5 JP2018516524A JP2018516524A JP2018530549A5 JP 2018530549 A5 JP2018530549 A5 JP 2018530549A5 JP 2018516524 A JP2018516524 A JP 2018516524A JP 2018516524 A JP2018516524 A JP 2018516524A JP 2018530549 A5 JP2018530549 A5 JP 2018530549A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- item
- compound according
- hydrogen
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 110
- 229910052739 hydrogen Inorganic materials 0.000 claims description 39
- 239000001257 hydrogen Substances 0.000 claims description 39
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 28
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 25
- 125000000217 alkyl group Chemical group 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 12
- 150000002431 hydrogen Chemical class 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229940011871 estrogen Drugs 0.000 claims description 3
- 239000000262 estrogen Substances 0.000 claims description 3
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 201000009273 Endometriosis Diseases 0.000 claims description 2
- 229940102550 Estrogen receptor antagonist Drugs 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 102000015694 estrogen receptors Human genes 0.000 claims description 2
- 108010038795 estrogen receptors Proteins 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 206010046885 vaginal cancer Diseases 0.000 claims description 2
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims 4
- -1 salt compound Chemical class 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 125000005843 halogen group Chemical group 0.000 description 5
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 2
- 229960002258 fulvestrant Drugs 0.000 description 2
- IPBQTKXTHVMANC-XHCCPWGMSA-N C[C@H](Cc1c2[nH]c3ccccc13)N(CC(C)(C)F)[C@@H]2c(cc1)ccc1OCCN1CC(CF)C1 Chemical compound C[C@H](Cc1c2[nH]c3ccccc13)N(CC(C)(C)F)[C@@H]2c(cc1)ccc1OCCN1CC(CF)C1 IPBQTKXTHVMANC-XHCCPWGMSA-N 0.000 description 1
- 208000017657 Menopausal disease Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562235900P | 2015-10-01 | 2015-10-01 | |
| US62/235,900 | 2015-10-01 | ||
| PCT/US2016/054549 WO2017059139A1 (en) | 2015-10-01 | 2016-09-29 | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020169604A Division JP7277424B2 (ja) | 2015-10-01 | 2020-10-07 | テトラヒドロ－１Ｈ－ピリド［３，４－ｂ］インドール抗エストロゲン薬物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018530549A JP2018530549A (ja) | 2018-10-18 |
| JP2018530549A5 true JP2018530549A5 (https=) | 2019-11-07 |
| JP6776348B2 JP6776348B2 (ja) | 2020-10-28 |
Family
ID=58427985
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018516524A Active JP6776348B2 (ja) | 2015-10-01 | 2016-09-29 | テトラヒドロ−１Ｈ−ピリド［３，４−ｂ］インドール抗エストロゲン薬物 |
| JP2020169604A Active JP7277424B2 (ja) | 2015-10-01 | 2020-10-07 | テトラヒドロ－１Ｈ－ピリド［３，４－ｂ］インドール抗エストロゲン薬物 |
| JP2023076673A Active JP7650316B2 (ja) | 2015-10-01 | 2023-05-08 | テトラヒドロ－１Ｈ－ピリド［３，４－ｂ］インドール抗エストロゲン薬物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020169604A Active JP7277424B2 (ja) | 2015-10-01 | 2020-10-07 | テトラヒドロ－１Ｈ－ピリド［３，４－ｂ］インドール抗エストロゲン薬物 |
| JP2023076673A Active JP7650316B2 (ja) | 2015-10-01 | 2023-05-08 | テトラヒドロ－１Ｈ－ピリド［３，４－ｂ］インドール抗エストロゲン薬物 |
Country Status (26)
| Country | Link |
|---|---|
| US (5) | US10292971B2 (https=) |
| EP (2) | EP3355884B1 (https=) |
| JP (3) | JP6776348B2 (https=) |
| KR (2) | KR20240142622A (https=) |
| CN (2) | CN108366996B (https=) |
| AU (4) | AU2016331065B2 (https=) |
| BR (2) | BR122023020677A2 (https=) |
| CA (1) | CA3000410A1 (https=) |
| CL (1) | CL2018000827A1 (https=) |
| CY (1) | CY1124669T1 (https=) |
| DK (1) | DK3355884T3 (https=) |
| ES (1) | ES2881398T3 (https=) |
| HR (1) | HRP20211124T1 (https=) |
| HU (1) | HUE055321T2 (https=) |
| IL (3) | IL286518B2 (https=) |
| LT (1) | LT3355884T (https=) |
| MX (2) | MX382269B (https=) |
| NZ (1) | NZ779654A (https=) |
| PL (1) | PL3355884T3 (https=) |
| PT (1) | PT3355884T (https=) |
| RS (1) | RS62133B1 (https=) |
| RU (1) | RU2745742C1 (https=) |
| SI (1) | SI3355884T1 (https=) |
| SM (1) | SMT202100433T1 (https=) |
| UA (1) | UA122346C2 (https=) |
| WO (1) | WO2017059139A1 (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI874834B (zh) | 2014-12-18 | 2025-03-01 | 瑞士商赫孚孟拉羅股份公司 | 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途 |
| KR20240142622A (ko) | 2015-10-01 | 2024-09-30 | 올레마 파마슈티컬스 인코포레이티드 | 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물 |
| LT3386500T (lt) | 2015-12-09 | 2022-12-27 | The Board Of Trustees Of The University Of Illinois | Selektyvūs estrogenų receptorių slopintojai benzotiofeno pagrindu |
| KR102479822B1 (ko) | 2016-02-05 | 2022-12-21 | 인벤티스바이오 엘엘씨 | 선택적 에스트로겐 수용체 분해제 및 이들의 용도 |
| WO2017182493A1 (en) | 2016-04-20 | 2017-10-26 | Astrazeneca Ab | Indazole derivatives for use in down-regulation of the estrogen receptor for the treatment of cancer |
| US10149839B2 (en) | 2016-07-25 | 2018-12-11 | Astrazeneca Ab | Chemical compounds |
| US20190201526A1 (en) * | 2016-09-07 | 2019-07-04 | The Wistar Institute Of Anatomy And Biology | Methods and Compositions for Treating Cancers by Inhibiting Estrogen Signaling in Myeloid-Derived Suppressor Cells |
| EP3640251B1 (en) | 2016-10-24 | 2021-12-08 | Astrazeneca AB | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer |
| WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
| MX2019008158A (es) | 2017-01-06 | 2019-12-09 | G1 Therapeutics Inc | Terapia de combinacion para el tratamiento del cancer. |
| PL3494116T3 (pl) | 2017-01-30 | 2020-04-30 | Astrazeneca Ab | Modulatory receptora estrogenowego |
| KR20190117582A (ko) | 2017-02-10 | 2019-10-16 | 쥐원 쎄라퓨틱스, 인크. | 벤조티오펜 에스트로겐 수용체 조정제 |
| CN111770924B (zh) * | 2018-04-04 | 2023-05-09 | 深圳福沃药业有限公司 | 用于治疗乳腺癌的雌激素受体降解剂 |
| CA3099155A1 (en) | 2018-05-14 | 2019-11-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| CR20200621A (es) | 2018-06-21 | 2021-02-03 | Hoffmann La Roche | Formas sólidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3 fluoropropil)azetidin-3-il)amino)fenil)-3-(metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos tricíclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos métodos para su uso |
| MX2021007687A (es) | 2018-12-24 | 2021-10-13 | Inventisbio Co Ltd | Sales novedosas de degradadores selectivos de receptores de estrogeno. |
| CA3138197A1 (en) | 2019-05-14 | 2020-11-19 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| KR20220034129A (ko) * | 2019-07-07 | 2022-03-17 | 올레마 파마슈티컬스 인코포레이티드 | 에스트로겐 수용체 길항제 요법 |
| EP4058464A1 (en) | 2019-11-13 | 2022-09-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| CA3169679A1 (en) * | 2020-03-06 | 2021-09-10 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-associated diseases |
| MX2022013391A (es) | 2020-04-24 | 2022-11-30 | Astrazeneca Ab | Pauta posologica para el tratamiento del cancer. |
| MX2022013258A (es) | 2020-04-24 | 2022-11-14 | Astrazeneca Ab | Formulaciones farmaceuticas. |
| US11848549B2 (en) * | 2020-09-15 | 2023-12-19 | Easy Solar Products, Inc. | Junction box with flashing for a tile surface |
| EP4267578A4 (en) | 2020-12-23 | 2024-11-20 | Recurium IP Holdings, LLC | ESTROGEN RECEPTOR MODULATORS |
| WO2022166983A1 (zh) * | 2021-02-08 | 2022-08-11 | 贝达药业股份有限公司 | 杂芳基并哌啶类衍生物及其药物组合物和应用 |
| JP2024516024A (ja) | 2021-05-03 | 2024-04-11 | ニューベイション・バイオ・インコーポレイテッド | 抗がん核内ホルモン受容体標的化化合物 |
| WO2023283329A1 (en) * | 2021-07-08 | 2023-01-12 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-associated diseases |
| WO2023091550A1 (en) * | 2021-11-18 | 2023-05-25 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-associated diseases |
| WO2023221122A1 (en) * | 2022-05-20 | 2023-11-23 | Olema Pharmaceuticals, Inc. | Salts and solid forms of an estrogen receptor antagonist |
| WO2023221123A1 (en) * | 2022-05-20 | 2023-11-23 | Olema Pharmaceuticals, Inc. | Crystalline forms of an estrogen receptor antagonist |
| CA3262155A1 (en) | 2022-08-11 | 2024-02-15 | Evexta Bio | COMPOUNDS FOR CANCER TREATMENT |
| AU2023324856A1 (en) | 2022-08-19 | 2025-01-30 | Olema Pharmaceuticals, Inc. | 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole derivatives as estrogen receptor modulators for the treatment of cancer |
| CA3261772A1 (en) | 2022-08-19 | 2024-02-22 | Olema Pharmaceuticals, Inc. | Estrogen Receptor Modulators and Their Uses |
| EP4573093A1 (en) | 2022-08-19 | 2025-06-25 | Olema Pharmaceuticals, Inc. | 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole derivatives as estrogen receptor modulators for the treatment of cancer |
| WO2024076633A1 (en) * | 2022-10-05 | 2024-04-11 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-mediated disorders |
| JP2025533900A (ja) * | 2022-10-05 | 2025-10-09 | オレマ ファーマシューティカルズ， インコーポレイテッド | エストロゲン受容体媒介性障害を治療する方法 |
| IL321349A (en) * | 2022-12-09 | 2025-08-01 | Olema Pharmaceuticals Inc | Dosage forms of estrogen receptor antagonists |
| WO2025106890A1 (en) * | 2023-11-17 | 2025-05-22 | Olema Pharmaceuticals, Inc. | Salts and solid forms of an estrogen receptor antagonist |
| WO2025168601A1 (en) | 2024-02-05 | 2025-08-14 | Evexta Bio | Quinazoline carboxamide azetidine compounds for use in treating hormone dependent diseases |
| WO2025175249A1 (en) | 2024-02-14 | 2025-08-21 | Olema Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| TW202543650A (zh) | 2024-03-08 | 2025-11-16 | 美商海爾達醫療運營公司 | 異雙官能化合物及其在治療疾病中之用途 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4418068A (en) | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| TW366342B (en) | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
| US5478847A (en) | 1994-03-02 | 1995-12-26 | Eli Lilly And Company | Methods of use for inhibiting bone loss and lowering serum cholesterol |
| DE69531476T2 (de) | 1994-09-12 | 2004-06-09 | Lilly Industries Ltd., Basingstoke | Serotonergische Modulatoren |
| US5998402A (en) | 1996-04-19 | 1999-12-07 | American Home Products Corporation | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
| US5780497A (en) | 1996-04-19 | 1998-07-14 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
| TW397821B (en) | 1996-04-19 | 2000-07-11 | American Home Produits Corp | 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof |
| US5880137A (en) | 1996-04-19 | 1999-03-09 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
| US6005102A (en) | 1997-10-15 | 1999-12-21 | American Home Products Corporation | Aryloxy-alkyl-dialkylamines |
| US6326392B1 (en) | 1997-11-06 | 2001-12-04 | American Home Products Corporation | Anti-estrogen plus progestin containing oral contraceptives |
| ID24568A (id) | 1997-11-06 | 2000-07-27 | American Home Prod | Kontrasepsi oral yang mengandung anti-estrogen plus progestin |
| US6479535B1 (en) | 1998-05-15 | 2002-11-12 | Wyeth | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations |
| US6583170B1 (en) | 1998-05-15 | 2003-06-24 | Wyeth | 2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol and estrogen formulations |
| GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| CO5271709A1 (es) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos |
| CO5271697A1 (es) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona |
| CO5271696A1 (es) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Procedimiento para reducir la morbilidad y el riesgo de mortalidad |
| CO5251465A1 (es) | 2000-01-26 | 2003-02-28 | Pfizer Prod Inc | Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol |
| US20020013327A1 (en) | 2000-04-18 | 2002-01-31 | Lee Andrew G. | Compositions and methods for treating female sexual dysfunction |
| AU2001271785A1 (en) | 2000-07-06 | 2002-01-21 | American Home Products Corporation | Combinations of statins, estrogenic agents and optionally estrogens |
| WO2002003990A2 (en) | 2000-07-06 | 2002-01-17 | Wyeth | Use of substituted insole compounds for treating excessive intraocular pressure |
| WO2002003986A2 (en) | 2000-07-06 | 2002-01-17 | Wyeth | Use of substituted indole compounds for treating breast disorders |
| WO2002003989A2 (en) | 2000-07-06 | 2002-01-17 | Wyeth | Use of substituted indole compounds for treating sphincter incontinence |
| AU2001273144A1 (en) | 2000-07-06 | 2002-01-21 | Wyeth | Use of substituted indole compounds for treating neuropeptide y-related conditions |
| MXPA03000170A (es) | 2000-07-06 | 2003-05-27 | Wyeth Corp | Combinaciones de un inhibidor de recaptacion de serotonina selectivo y agentes estrogenicos. |
| AU7178301A (en) | 2000-07-06 | 2002-01-21 | American Home Prod | Methods for increasing nitric oxide synthase activity |
| AU2001271784A1 (en) | 2000-07-06 | 2002-01-21 | Wyeth | Therapy for prosthesis-related bone degeneration |
| AR030064A1 (es) | 2000-07-06 | 2003-08-13 | Wyeth Corp | Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos |
| AU2001273125A1 (en) | 2000-07-06 | 2002-01-21 | American Home Products Corporation | Combinations of bisphosphonates, estrogenic agents and optionally estrogens |
| EP1177787A3 (en) | 2000-07-28 | 2003-09-10 | Pfizer Products Inc. | Use of an estrogen agonist/antagonist for treating cataracts |
| JP2004507465A (ja) | 2000-08-11 | 2004-03-11 | ワイス | エストロゲン受容体陽性癌腫の治療方法 |
| EP1192945A3 (en) | 2000-09-21 | 2004-03-03 | Pfizer Products Inc. | Use of an estrogen agonist/antagonist for treating osteoarthritis |
| IL145838A (en) | 2000-10-16 | 2008-11-03 | Pfizer Prod Inc | Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis |
| AU781168B2 (en) | 2001-01-26 | 2005-05-12 | Pfizer Products Inc. | Method of treating certain cancers using an estrogen agonist/antagonist |
| PL374215A1 (en) | 2001-08-11 | 2005-10-03 | Bristol-Myers Squibb Pharma Company | Selective estrogen receptor modulators |
| EP1720862A1 (en) | 2004-02-03 | 2006-11-15 | Eli Lilly And Company | Kinase inhibitors |
| US7745625B2 (en) | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
| US7767689B2 (en) | 2004-03-15 | 2010-08-03 | Ptc Therapeutics, Inc. | Carboline derivatives useful in the treatment of cancer |
| US8076352B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
| UA92317C2 (ru) | 2004-03-15 | 2010-10-25 | Пи-Ти-Си ТЕРАПЬЮТИКС, ИНК. | Производные карболина, пригодные для ингибирования развития кровеносных сосудов |
| AU2006206446A1 (en) | 2005-01-21 | 2006-07-27 | Janssen Pharmaceutica N.V. | Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors |
| RU58668U1 (ru) | 2006-06-05 | 2006-11-27 | Открытое акционерное общество "Нижегородский машиностроительный завод" | Водогрейный котел |
| WO2010138695A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating neurofibromatosis |
| MX373926B (es) | 2009-05-27 | 2020-07-10 | Ptc Therapeutics Inc | Metodos para tratar cancer y estados no neoplasicos. |
| US20120202801A1 (en) | 2009-05-27 | 2012-08-09 | Liangxian Cao | Methods for treating breast cancer |
| RS56042B1 (sr) | 2010-06-10 | 2017-09-29 | Seragon Pharmaceuticals Inc | Modulatori estrogenih receptora i njihove upotrebe |
| US8853423B2 (en) | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
| GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| CA2819299A1 (en) * | 2010-12-24 | 2012-06-28 | Merck Sharp & Dohme B.V. | N-substituted azetidine derivatives |
| WO2013090829A1 (en) * | 2011-12-14 | 2013-06-20 | Aragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| EP2791128A4 (en) | 2011-12-16 | 2015-04-22 | Olema Pharmaceuticals Inc | NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF |
| UY35590A (es) | 2013-05-28 | 2014-11-28 | Astrazeneca Ab | Nuevos compuestos para el tratamiento del cáncer |
| WO2014203132A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Substituted benzopyran compounds, compositions and uses thereof |
| CA2915534A1 (en) | 2013-06-19 | 2014-12-24 | Seragon Pharmaceuticals, Inc. | Azetidine estrogen receptor modulators and uses thereof |
| EA031077B1 (ru) | 2013-06-19 | 2018-11-30 | Серагон Фармасьютикалз, Инк. | Модулятор рецептора эстрогена и его применения |
| WO2014203129A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Combinations of benzopyran compounds, compositions and uses thereof |
| US20170336055A1 (en) * | 2014-10-23 | 2017-11-23 | Oy Mtg-Meltron Ltd | Lighting apparatus for hazardous areas |
| GB2570237B (en) * | 2014-10-31 | 2019-11-06 | Karsten Mfg Corp | Grooves of golf club heads and methods to manufacture grooves of golf club heads |
| TWI874834B (zh) * | 2014-12-18 | 2025-03-01 | 瑞士商赫孚孟拉羅股份公司 | 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途 |
| WO2016097071A1 (en) | 2014-12-18 | 2016-06-23 | F. Hoffmann-La Roche Ag | Estrogen receptor modulators and uses thereof |
| US20160175284A1 (en) | 2014-12-18 | 2016-06-23 | Genentech, Inc. | Estrogen receptor modulators and uses thereof |
| WO2016174551A1 (en) | 2015-04-27 | 2016-11-03 | Pfizer Inc. | Anti-estrogenic compounds |
| KR20240142622A (ko) | 2015-10-01 | 2024-09-30 | 올레마 파마슈티컬스 인코포레이티드 | 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물 |
| CN109843882A (zh) | 2016-06-16 | 2019-06-04 | 豪夫迈·罗氏有限公司 | 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途 |
| US20180002344A1 (en) | 2016-06-16 | 2018-01-04 | Genentech, Inc. | Heteroaryl estrogen receptor modulators and uses thereof |
| EP3640251B1 (en) | 2016-10-24 | 2021-12-08 | Astrazeneca AB | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer |
| TWI702219B (zh) | 2018-07-12 | 2020-08-21 | 美商美國禮來大藥廠 | 選擇性雌激素受體降解劑 |
| CN112424205B (zh) | 2018-07-12 | 2023-10-31 | 伊莱利利公司 | 选择性的雌激素受体降解剂 |
-
2016
- 2016-09-29 KR KR1020247031670A patent/KR20240142622A/ko active Pending
- 2016-09-29 LT LTEP16852640.8T patent/LT3355884T/lt unknown
- 2016-09-29 MX MX2018003929A patent/MX382269B/es unknown
- 2016-09-29 WO PCT/US2016/054549 patent/WO2017059139A1/en not_active Ceased
- 2016-09-29 CN CN201680067297.0A patent/CN108366996B/zh active Active
- 2016-09-29 SI SI201631280T patent/SI3355884T1/sl unknown
- 2016-09-29 EP EP16852640.8A patent/EP3355884B1/en active Active
- 2016-09-29 CN CN202110308336.4A patent/CN113248494A/zh active Pending
- 2016-09-29 PT PT168526408T patent/PT3355884T/pt unknown
- 2016-09-29 NZ NZ779654A patent/NZ779654A/en unknown
- 2016-09-29 US US15/764,988 patent/US10292971B2/en active Active
- 2016-09-29 UA UAA201804591A patent/UA122346C2/uk unknown
- 2016-09-29 SM SM20210433T patent/SMT202100433T1/it unknown
- 2016-09-29 AU AU2016331065A patent/AU2016331065B2/en active Active
- 2016-09-29 KR KR1020187011902A patent/KR102710603B1/ko active Active
- 2016-09-29 RU RU2018115696A patent/RU2745742C1/ru active
- 2016-09-29 RS RS20210924A patent/RS62133B1/sr unknown
- 2016-09-29 HU HUE16852640A patent/HUE055321T2/hu unknown
- 2016-09-29 DK DK16852640.8T patent/DK3355884T3/da active
- 2016-09-29 IL IL286518A patent/IL286518B2/en unknown
- 2016-09-29 PL PL16852640T patent/PL3355884T3/pl unknown
- 2016-09-29 BR BR122023020677-0A patent/BR122023020677A2/pt not_active Application Discontinuation
- 2016-09-29 JP JP2018516524A patent/JP6776348B2/ja active Active
- 2016-09-29 IL IL310489A patent/IL310489A/en unknown
- 2016-09-29 CA CA3000410A patent/CA3000410A1/en active Pending
- 2016-09-29 HR HRP20211124TT patent/HRP20211124T1/hr unknown
- 2016-09-29 ES ES16852640T patent/ES2881398T3/es active Active
- 2016-09-29 BR BR112018006121-2A patent/BR112018006121B1/pt active IP Right Grant
- 2016-09-29 EP EP21164199.8A patent/EP3912680A1/en active Pending
-
2018
- 2018-03-26 IL IL258363A patent/IL258363B/en unknown
- 2018-03-28 MX MX2021005214A patent/MX2021005214A/es unknown
- 2018-03-29 CL CL2018000827A patent/CL2018000827A1/es unknown
-
2019
- 2019-04-23 US US16/391,686 patent/US10624878B2/en active Active
-
2020
- 2020-04-17 US US16/852,272 patent/US11229630B2/en active Active
- 2020-10-07 JP JP2020169604A patent/JP7277424B2/ja active Active
-
2021
- 2021-07-22 CY CY20211100665T patent/CY1124669T1/el unknown
- 2021-07-22 AU AU2021206861A patent/AU2021206861B2/en active Active
- 2021-12-06 US US17/542,908 patent/US11672785B2/en active Active
-
2023
- 2023-04-28 AU AU2023202620A patent/AU2023202620B2/en active Active
- 2023-05-02 US US18/142,068 patent/US20240226073A9/en active Pending
- 2023-05-08 JP JP2023076673A patent/JP7650316B2/ja active Active
-
2025
- 2025-05-15 AU AU2025203540A patent/AU2025203540A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018530549A5 (https=) | ||
| HRP20211124T1 (hr) | TETRAHIDRO-1H-PIRIDO[3,4-b]INDOL ANTI-ESTROGENI LIJEKOVI | |
| JP2016531871A5 (https=) | ||
| JP2015514808A5 (https=) | ||
| JP2019524883A5 (https=) | ||
| JP2010077141A5 (https=) | ||
| JP2017514910A5 (https=) | ||
| JP2018522879A5 (https=) | ||
| JP2016528301A5 (https=) | ||
| JP2016503799A5 (https=) | ||
| JP2020506951A5 (https=) | ||
| MX2025000126A (es) | Esteroides neuroactivos alfa.-hidroxi-17.beta.-amida y composiciones de los mismos | |
| JP2020097577A5 (https=) | ||
| JP2017519754A5 (https=) | ||
| JP2009504763A5 (https=) | ||
| JP2016525102A5 (https=) | ||
| JP2017517565A5 (https=) | ||
| JP2009523760A5 (https=) | ||
| JP2017531619A5 (https=) | ||
| JP2019510027A5 (https=) | ||
| JP2013542261A5 (https=) | ||
| JP2015516427A5 (https=) | ||
| JP2020507566A5 (https=) | ||
| RU2018113718A (ru) | Новые соединения | |
| JP2018527301A5 (ja) | アジリジン含有ｄｎａアルキル化剤 |